Company Information
- Type:
- Company
- Country:
- Belgium
- Sector:
- Pharmaceuticals & Biotechnology
- Ownership:
- Publicly Listed
- Global Compact Status:
- Active
- Participant Since
- 13 January 2021 Letter of Commitment
- Next Communication on Progress (COP) due on:
- 31 July 2025
Engagements
Affiliated Subsidiaries
| Country | Company Name |
|---|---|
| France | UCB Pharma S.A. |
| United States of America | UCB, Inc. |
| Switzerland | UCB Farchim SA |
| Italy | UCB Pharma SpA |
| Spain | UCB PHARMA, S.A. |
Communication On Progress
| Published On | Title | Level/Status |
|---|---|---|
| 01-Aug-2024 | 2024 Communication on Progress | Submitted |
| 03-Mar-2022 | UCB Integrated Annual report | Active |
| 29-Nov-2021 | Grace Letter | Not applicable |
Note: Responsibility for the content of participants' public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact.
Note on levels: Not applicable refers to the period when the Communication on Progress (CoP) did not require differentiation levels. With the new CoP , for the 2022 Early Adopter Programme, and for 2023, there will be no differentiation levels.